What is your preferred therapy for CDK12-altered advanced prostate cancer, outside clinical trial?
Would you treat with PARP inhibitor or Check-Point Inhibitor?
Answer from: Medical Oncologist at Community Practice
CDK12-mutated prostate cancers are aggressive and typically respond less favorably to AR-directed therapies. The CDK12 gene was on the eligibility list for the PROfound study, so olaparib could be used for mCRPC patients who have progressed on at least one AR-directed agent. In the CDK12-altered sub...
Sign in or Register to read more